---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-004738"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2026-02-03T23:59:59+00:00"
generated_at: "2026-05-16T05:21:22.789523+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Amneal reprices $2.1B term loan, margin cut 50 bps, saving ~$11M/year

## Summary
- Repricing amendment reduces interest rate margin by 50 bps to SOFR+3.00% or Base Rate+2.00%.
- Total Amendment No. 2 Term Loans of ~$2.095B, including ~$134.7M new term loan.
- Annualized cash interest savings estimated at ~$11 million.
- Maturity unchanged at August 1, 2032.
- Proceeds used to refinance existing Amendment No. 1 Term Loans.

## SEC filing metadata
- accession: 0001628280-26-004738
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2026-02-03T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/0001628280-26-004738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/amrx-20260202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-004738
- JSON: https://secwatch.observer/filing/0001628280-26-004738.json
- Plain text: https://secwatch.observer/filing/0001628280-26-004738.txt

## Key facts
- Debt Financings
  Amneal Pharmaceuticals, Inc. amended credit facility of $1,960,076,527.50 with JPMorgan Chase Bank, N.A. at 2.00% (for base rate) and 3.00% (for SOFR) maturing August 1, 2032.
  - Instrument: credit facility
  - Principal: $1,960,076,527.50
  - Counterparty: JPMorgan Chase Bank, N.A.
  - Rate: 2.00% (for base rate) and 3.00% (for SOFR)
  - Maturity: August 1, 2032
  - Event: amendment
  source text: on a cashless basis, its term loans outstanding immediately prior to the Repricing Amendment (the “Existing Term Loans) into new term loans with an aggregate principal amount of $1,960,076,527.50 (collectively, the “Converted Amendment No. 2 Term Loans”) and (y) the Company incurred a new term loan with an aggregate principal amount of $134,673,472.50 (the “Additional
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/0001628280-26-004738-index.htm
- Debt Financings
  Amneal Pharmaceuticals, Inc. incurred term loan of $134,673,472.50 with JPMorgan Chase Bank, N.A. maturing August 1, 2032.
  - Instrument: term loan
  - Principal: $134,673,472.50
  - Counterparty: JPMorgan Chase Bank, N.A.
  - Maturity: August 1, 2032
  - Event: incurrence
  source text: the Company incurred a new term loan with an aggregate principal amount of $134,673,472.50 (the "Additional Amendment No. 2 Term Loan")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/0001628280-26-004738-index.htm
- Material Agreements
  Amneal Pharmaceuticals, Inc. amended Amendment No. 2 to Term Loan Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto (effective 2026-02-02).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto
  - Effective: 2026-02-02
  source text: On February 2, 2026, Amneal Pharmaceuticals, Inc.’s (the "Corporation") subsidiary, Amneal Pharmaceuticals LLC (the “Company” or, the “Borrower”), and certain of the Company’s subsidiaries, as guarantors, entered into that certain Amendment No. 2 to Term Loan Credit Agreement (the “Repricing Amendment”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), and the other lenders party thereto consenting to the Repricing Amendment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/0001628280-26-004738-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.